Teva Pharmaceuticals, Inc.
1090 Horsham Road
P.O. Box 1090
About Teva Pharmaceuticals, Inc.
TEVA Pharmaceuticals USA is the nation’s leading generic manufacturer, marketing the broadest product line in the U.S. with over 300 products. The company leads the industry in the number of new and total retail prescriptions in the U.S. Teva Pharmaceuticals USA employs approximately 1,200 people.
We believe that our quality people and the quality products that we market enhance the quality of life of patients and consumers throughout the world. Our achievements are possible due to the diligent efforts and complete dedication of these employees and our employees worldwide.
Part of what makes us successful is that as a company, we constantly analyze where we are today and where we need to be tomorrow. Teva USA's management philosophy is to develop leaders and their associates so that they may achieve professional and career success in the pharmaceutical business.
It is in this spirit that we provide our employees with many training and development opportunities necessary to cultivate and improve their skills, enhancing their career potential and growth. Teva USA views continuing education and development as the means to acquire the tools and techniques necessary to keep its employees and the organization in the forefront of leadership and good business practice.
Teva USA's future as the leader in the generic pharmaceutical industry hinges on both our individual and collective abilities. For these reasons, we rely on our diversity, creative solutions, teamwork and commitment to quality and customer service, which have built a tradition of customer satisfaction, value and profitability.
At Teva Pharmaceuticals USA, in addition to hard work, we also believe in having fun. We reinforce this belief through the events and activities that we sponsor. Company activities include an Easter Egg Hunt, a well-attended company picnic, and an annual Halloween pumpkin-carving contest. We also have an Activities Committee that organizes trips to local sporting events, short day trips, and theatre events. For the sports-minded, we have clubs to join such as running clubs and ski clubs. There's at least one activity or club to suit each and every employee!
As an organization, Teva is active in the community, involved in everything from sponsoring local theatre groups, sports teams and school programs, to donating medicines for humanitarian relief work around the globe.
Teva USA has an individual spirit of giving. Throughout the year employees participate in a variety of community enrichment drives. For example, the American Red Cross is welcomed here for organized Blood Drives. Employees also make contributions to various on-site programs such as food and clothing drives and children's gift-giving programs.
107 articles with Teva Pharmaceuticals, Inc.
Allergan has gone to great lengths to defend the patents for its blockbuster dry-eye drug Restasis and it looks like the company will have to head back to court again.
5/18/2018Amgen and Novartis scored a big win in the migraine market late Thursday when the U.S. Food and Drug Administration approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of data from the Phase III HALO study...
Shares of Perrigo have yet to rebound following the company’s weekend announcement that it expects the U.S. Food and Drug Administration to issue a Complete Response Letter for its generic version of Teva’s ProAir asthma inhaler.
AstraZeneca and its biologics research-and-development arm, MedImmune, indicated that its Fasenra (benralizumab) did not meet its primary endpoint in patients with moderate to very severe COPD.
Pharmaceutical execs who leave their positions with big pharmaceutical companies, unless opting to retire for good, often move to leadership positions at other big companies. There are other choices.
Patent fights are nothing new in the pharmaceutical industry but a new report shows that during 2017 the number of legal battles of pharmaceutical patents increased by 30 percent.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
5/3/2018Regeneron has halted high dose treatment of a Phase III osteoarthritis drug following a risk-benefit assessment conducted by an Independent Data Monitoring Committee.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.
Teva to Present AUSTEDO® (deutetrabenazine) Tablets Data at the American Psychiatric Association 2018 Annual Meeting
Three abstracts evaluate the long-term safety and efficacy of AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults In addition, new health economics data assess quality of life and health burden impact among patients
Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mL
Teva Pharmaceutical Industries Ltd. announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE® (glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatment of relapsing forms of multiple sclerosis (RMS).
Amgen’s New Products Deliver Double-Digit Growth While Facing Down Pricing Pressure for New Migra...
4/25/2018In its first-quarter earnings report, Thousand Oaks, California-based Amgen cited total revenue for the quarter of $5.6 billion, up 2 percent compared to the first quarter of 2017. But the quarter’s earnings were driven by double-digit growth for new and recently launched products.
The FDA Giveth and Taketh Away: Grants Pfizer's MenB Breakthrough Therapy Designation and Turns D...
4/23/2018The FDA granted Pfizer’s Trumenba, a vaccine for meningococcal B disease in children ages one to nine years, Breakthrough Therapy Designation and declined to approve its biosimilar of Roche's Herceptin for breast cancer.
Shares of Novartis are down nearly 3 percent this morning after the company reported a sharp decline in generic drugs and sales results from key branded medicines that missed analysts’ projections for the first quarter.
Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines.
Amgen announced final data from its Phase IIIb LIBERTY clinical trial of Aimovig (erenumab), with positive results likely to lead to a blockbuster drug for migraine sufferers.
Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology
Two platform presentations and 19 posters explore the potential of fremanezumab as an investigational treatment option for the prevention of migraine COPAXONE® (glatiramer acetate injection) and AUSTEDO® (deutetrabenazine) tablets data highlight Teva’s ongoing clinical research
The FDA issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion. Teva Pharmaceutical Industries signed a deal in 2016 with Celltrion to commercialize the two biosimilars.